Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04162223 · ClinicalTrials.gov registry record · Early Phase 1
Hepatitis B Vaccine in Seniors
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
NCT04162223 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 52 participants.
The verdict
NCT04162223, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The first purpose of this study is to test the body's protective reaction (making antibodies) to a licensed hepatitis B vaccine (Recombivax-HB) after it is injected either in the arm fat or muscle. Hepatitis B virus is an important cause of liver disease in humans. More than 21% of healthy adults over age 60 years demonstrate evidence of previous Hepatitis B infection using a common blood test. The second purpose of this study is to learn more information about other reasons (such as body fat content, gene types, etc.), why older people respond less well than younger people to vaccines. The Investigators will also learn more about the ability of certain white blood cells, called T cells, to respond to protein signals in the blood. T cells do not seem to respond as well to these protein signals as individuals age. The Investigators will compare results to a younger group of volunteers who have also been vaccinated with hepatitis B vaccine.
Interventions
- BIOLOGICAL Subcutaneous fat injection of Recombivax-HB
- BIOLOGICAL Intramuscular injection of Recombivax-HB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2000-03-29 |
| Est. Completion | 2003-05-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04162223
The ClinicalTrials.gov registry entry for NCT04162223 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Subcutaneous fat injection of Recombivax-HB is the first listed.
NCT04162223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04162223 about?
NCT04162223 is a clinical study titled "Hepatitis B Vaccine in Seniors". The first purpose of this study is to test the body's protective reaction (making antibodies) to a licensed hepatitis B vaccine (Recombivax-HB) after it is injected either in the arm fat or muscle. Hepatitis B virus is an important cause of liver disease in humans. More than 21% of healthy adults ov...
What is the current status of trial NCT04162223?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2000-03-29. Estimated completion is 2003-05-20.
What interventions are being tested in trial NCT04162223?
The interventions under investigation include: Subcutaneous fat injection of Recombivax-HB (BIOLOGICAL), Intramuscular injection of Recombivax-HB (BIOLOGICAL).
Who is sponsoring clinical trial NCT04162223?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.